var data={"title":"Clonidine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Clonidine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5928?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=clonidine-drug-information\" class=\"drug drug_general\">see &quot;Clonidine: Drug information&quot;</a> and <a href=\"topic.htm?path=clonidine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Clonidine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708678\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Epidural use: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The 500 mcg/mL strength product should be diluted prior to use in an appropriate solution.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Note: Epidural clonidine is not recommended for obstetrical, postpartum, or perioperative pain management. The risk of hemodynamic instability, especially hypotension and bradycardia, from epidural clonidine may be unacceptable in these patients. However, in a rare obstetrical, postpartum or perioperative patient, potential benefits may outweigh the possible risks.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153485\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Catapres;</li>\n      <li>Catapres-TTS-1;</li>\n      <li>Catapres-TTS-2;</li>\n      <li>Catapres-TTS-3;</li>\n      <li>Duraclon;</li>\n      <li>Kapvay</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153486\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Catapres;</li>\n      <li>Dixarit</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051807\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Adrenergic Agonist Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Alpha-Adrenergic Agonist</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Analgesic, Nonopioid</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antihypertensive Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12669157\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosing is expressed as the salt (clonidine hydrochloride) unless otherwise noted. Compounded oral suspensions may be available in multiple concentrations (eg, up to 10 times more concentrated); precautions should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented as mcg or mg as appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neonatal abstinence syndrome (opioid withdrawal):</b> <i>Weight-directed dosing:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preterm neonate (GA &lt;35 weeks): Very limited data available: Oral: 0.5 to 1 <b>mcg</b>/kg/dose every 6 hours was used in 14 neonates to prevent (n=10) or treat (n=4) either iatrogenic opioid dependency or neonatal abstinence syndrome; within the study group, the reported median GA: 26 weeks and 2 days (range: 24 to 40 weeks), mean PNA at time of treatment: 4.1 weeks; prior to clonidine the mean Finnegan score was 6.4 (range: 0 to 20) and after cessation of clonidine, the mean Finnegan score was 1.9 (range: 0 to 5); clonidine was stopped or tapered by 0.25 <b>mcg</b>/kg every 6 hours once patients were stabilized (Leikin 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GA &ge;35 weeks: Limited data available: Oral: 0.5 to 1 <b>mcg</b>/kg/dose every 4 to 6 hours (Agthe 2009; Hoder 1984; Hudak 2012). In a randomized, controlled, comparative trial in 80 neonates with NAS, patients receiving combination treatment (n=40, mean modified Finnegan score [MFS] at start of treatment: 12 &plusmn; 3) with 1 <b>mcg</b>/kg/dose every 4 hours of clonidine plus diluted opium tincture (DTO) demonstrated a decreased length of DTO therapy and lower opioid doses compared to DTO alone (Agathe 2009). In a smaller, open-label trial of seven patients, clonidine was administered as an initial dose of 0.5 to 1 <b>mc</b>g/kg, then gradually increased over 1 to 2 days to maintenance dose of 3 to 5 <b>mcg</b>/kg/<b>day</b> in divided doses every 4 to 6 hours. Once the patient was stable, doses were weaned as tolerated by 25% of the total daily dose every other day. Six of the seven infants showed a marked reduction in the signs and symptoms of withdrawal (Hoder 1984). Higher doses were described in a prospective, nonblinded study of 66 neonates with NAS who were randomized to receive morphine in combination with clonidine (n=32; baseline MFS: 13.4 &plusmn; 3.2) or phenobarbital (n=34; baseline MFS: 11.9 &plusmn; 2.1). Clonidine doses were determined based on MFS and ranged from 1.5 to 3 <b>mcg</b>/kg/dose every 6 hours. Overall, adjunct treatment with clonidine decreased the length of morphine treatment days compared to no adjunct therapy. Compared to adjunct morphine/phenobarbital group, patients in the morphine/clonidine group had a longer nonsignificant inpatient treatment duration (~7 days) with no outpatient therapy required, so overall length of NAS treatment was shorter in the clonidine treatment arm (Surran 2013). A small, randomized, double blind trial of 31 neonates with NAS evaluated clonidine (n=16, baseline MFS: 12.4 &plusmn; 1.4) as primary treatment for NAS compared to morphine. Clonidine was initiated at 0.625 <b>mcg</b>/kg/dose every 3 hours, doses were increased as needed by 25% of the initial dose every 24 hours to a maximum dose of 12 <b>mcg</b>/kg/day in divided doses every 3 hours. Doses were weaned as tolerated by 10% every other day. Patients receiving clonidine had significant improvements in NICU network neurobehavioral scale measurements and had a shorter duration of treatment compared to patients treated with morphine. Optimal dose reported in this study was 1 mcg/kg/dose every 3 hours (Bada 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051799\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=clonidine-drug-information\" class=\"drug drug_general\">see &quot;Clonidine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosing is expressed as the salt (clonidine hydrochloride) unless otherwise noted. Formulations of clonidine (immediate release vs extended release) are not interchangeable on a mg per mg basis due to different pharmacokinetic profiles. Compounded oral suspensions may be available in multiple concentrations (eg, up to a 10-times more concentrated); precautions should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented as mcg or mg as appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Analgesia:</b> Children and Adolescents: Epidural: Continuous infusion: Initial: 0.5 <b>mcg</b>/kg/<b>hour</b>; adjust with caution, based on clinical effect; usual range: 0.5 to 2 <b>mcg</b>/kg/<b>hour</b>; do not exceed adult doses. Do not discontinue clonidine abruptly; if needed, gradually reduce dose over 2 to 4 days to avoid withdrawal symptoms. Manufacturer suggests use reserved for cancer patients with severe intractable pain, unresponsive to other opioid analgesics, or epidural or spinal opioids; has also been used for pediatric chronic pain syndromes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Attention-deficit/hyperactivity disorder (ADHD):</b> Children &ge;6 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Immediate release: Limited data available (Pliszka 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&le;45 kg: Initial: 0.05 mg at bedtime; sequentially increase every 3 to 7 days in 0.05 mg/day increments given as 0.05 mg twice daily, then 3 times daily, then 4 times daily; maximum daily dose weight-dependent: Patient weight: 27 to 40.5 kg: 0.2 mg/<b>day</b>; patient weight: 40.5 to 45 kg; 0.3 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;45 kg: Initial: 0.1 mg at bedtime; sequentially increase every 3 to 7 days in 0.1 mg/day increments given as 0.1 mg twice daily, then 3 times daily, then 4 times daily; maximum daily dose: 0.4 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Extended release (Kapvay): Initial: 0.1 mg at bedtime; increase in 0.1 mg/day increments every 7 days until desired response; doses should be administered twice daily in the morning and at bedtime (either split equally or with the higher split dosage given at bedtime); maximum daily dose: 0.4 mg/<b>day</b>. <b>Note:</b> When discontinuing therapy, taper daily dose by &le;0.1 mg every 3 to 7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Topical: Transdermal patch: Limited data available: Children and adolescents may be switched to the transdermal delivery system after oral therapy is titrated to an optimal and stable dose; a transdermal dose approximately equivalent to the total oral daily dose may be used (Hunt 1990).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Clonidine tolerance test (test of growth hormone release from the pituitary):</b> Limited data available: Children and Adolescents: Oral: Immediate release: 0.15 mg/m<sup>2</sup> or 5 <b><b>mcg</b></b>/kg as a single dose; maximum dose: 0.25 mg (250 mcg) (Lanes 1982; Richmond 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Conduct disorder/oppositional-defiant disorder with or without ADHD:</b> Limited data available; efficacy results variable (Connor 2010; Pringsheim 2015): Children &ge;5 years and Adolescents: Oral: Immediate release: Initial: 0.05 mg/day; gradual titration every 3 to 7 days in 0.05 mg increments to a 2 or 3 times daily dose schedule has been used most frequently, some patients may require 4 daily doses; usual final dose range: 0.2 to 0.3 mg/day in 2 to 3 divided doses, reported overall range: 0.15 to 0.4 mg/day in divided doses; most reported experience in patients with ADHD comorbidity (Connor 2000; Hazell 2003; Kemph 1993; Palumbo 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypertension:</b>  Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight-directed dosing: Children and Adolescents 1 to 17 years: Initial: 5 to 10 <b>mcg</b>/kg/day in divided doses every 8 to 12 hours; increase gradually as needed; usual range: 5 to 25 <b>mcg</b>/kg/day in divided doses every 6 hours; maximum daily dose: 0.9 mg/<b>day</b> (Kavey 2010; Rocchini 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Fixed dosing: Children and Adolescents &ge;12 years: Initial: 0.1 mg twice daily; increase gradually, if needed, by 0.1 mg/day at weekly intervals; usual maintenance dose: 0.2 to 0.6 mg/day in divided doses; maximum recommended daily dose: 2.4 mg/<b>day</b> (rarely required) (NHBPEP 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Topical: Transdermal patch: Limited data available: Children and Adolescents: May be switched to the transdermal delivery system after oral therapy is titrated to an optimal and stable dose; a transdermal dose approximately equivalent to the total oral daily dose may be used (Hunt 1990).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypertension, urgency and emergency:</b> Limited data available: Children and Adolescents 1 to 17 years: Oral: Immediate release: 0.05 to 0.1 mg/dose; may repeat dose(s) up to a maximum total dose of 0.8 mg (NHBPEP 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Neuropathic pain:</b>  Limited data available: Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Immediate release: Some centers use the following doses (Galloway 2000): Initial: 2 <b>mcg</b>/kg/dose every 4 to 6 hours; increase incrementally over several days; range: 2 to 4 <b>mcg</b>/kg/dose every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Topical: Transdermal patch: May be switched to the transdermal delivery system after oral therapy is titrated to an optimal and stable dose; a transdermal dose approximately equivalent to the total oral daily dose may be used (Galloway 2000; Hunt 1990).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sedation, critically ill patients: </b>Limited data available: Infants, Children, and Adolescents: Oral: Immediate release: Usual reported dose: 1 to 5 <b>mcg</b>/kg/dose every 6 to 8 hours; maximum dose: 200 <b>mcg</b>/dose; reported daily dose range: 2 to 20 <b>mcg</b>/kg/<b>day; </b>Avoid abrupt discontinuation to prevent withdrawal symptoms (Arenas-Lopez 2004; Capino 2016; Duffett 2014; Playfor 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tic disorders and Tourette syndrome:</b> Limited data available; greater efficacy shown in patients with ADHD comorbidity (Weisman 2013): Children &ge;7 years and Adolescents: Oral: Immediate release: Initial: 0.025 to 0.05 mg/day; gradual titration to a 3 to 4 times daily schedule using small increments (0.025 mg); usual daily dose: 0.1 to 0.4 mg/day in 3 to 4 divided doses (AACAP [Murphy 2013]; Pringsheim 2012; The Tourette Syndrome Study Group 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypertension:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Immediate release: Initial dose: 0.1 mg twice daily (maximum recommended dose: 2.4 mg/day); usual dose range: 0.1 to 0.2 mg twice daily (ASH/ISH [Weber 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Transdermal: Initial: 0.1 mg/24-hour patch applied once every 7 days and increase by 0.1 mg at 1- to 2-week intervals (dosages &gt;0.6 mg/24 hours do not improve efficacy); usual dose range: 0.1 to 0.3 mg/24 hour-patch applied once every 7 days (ASH/ISH [Weber 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Conversion from oral to transdermal:</i> <b>Note:</b> If transitioning from oral to transdermal therapy, overlap oral regimen for 1 to 2 days; transdermal route takes 2 to 3 days to achieve therapeutic effects. An example transition is below:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Day 1: Place Catapres-TTS 1; administer 100% of oral dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Day 2: Administer 50% of oral dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Day 3: Administer 25% of oral dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Day 4: Patch remains; no further oral supplement necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Conversion from transdermal to oral:</i> After transdermal patch removal, therapeutic clonidine levels persist for ~8 hours and then slowly decrease over several days. Consider starting oral clonidine no sooner than 8 hours after patch removal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pain management:</b> Epidural (continuous infusion): Reserved for cancer patients with severe intractable pain, unresponsive to other opioid analgesics: Initial: 30 <b>mcg/hour</b>; titrate as required for relief of pain or presence of side effects; minimal experience with doses &gt;40 <b>mcg/hour</b>; should be considered an adjunct to intraspinal opioid therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents: Oral [extended release (Kapvay)], epidural: The manufacturer recommends dosage adjustment according to degree of renal impairment; however, there are no specific dosage adjustment provided in the labeling (has not been studied). Bradycardia, sedation, and hypotension may be more likely to occur in patients with renal failure; drug is primarily eliminated unchanged in the urine; consider using doses at the lower end of the dosage range; monitor patients closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Oral (immediate release), transdermal, epidural: The manufacturer recommends dosage adjustment according to degree of renal impairment; however, no specific dosage adjustment provided in manufacturer's labeling. Bradycardia, sedation, and hypotension may be more likely to occur in patients with renal failure; half-life significantly prolonged in patients with severe renal failure; consider use of lower initial doses and monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Not dialyzable  (0% to 5%); supplemental dose is not necessary. Oral antihypertensive drugs given preferentially at night may reduce the nocturnal surge of blood pressure and minimize the intradialytic hypotension that may occur when taken the morning before a dialysis session (K/DOQI 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing  adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153455\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Patch Weekly, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Catapres-TTS-1: 0.1 mg/24 hr (4 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Catapres-TTS-2: 0.2 mg/24 hr (4 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Catapres-TTS-3: 0.3 mg/24 hr (4 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.1 mg/24 hr (1 ea, 4 ea); 0.2 mg/24 hr (1 ea, 4 ea); 0.3 mg/24 hr (1 ea, 4 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Epidural, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Duraclon: 100 mcg/mL (10 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Epidural, as hydrochloride [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Duraclon: 100 mcg/mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Duraclon: 500 mcg/mL (10 mL) [pyrogen free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mcg/mL (10 mL); 500 mcg/mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Catapres: 0.1 mg [scored; contains brilliant blue fcf (fd&amp;c blue #1), corn starch, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Catapres: 0.2 mg, 0.3 mg [scored; contains corn starch, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.1 mg, 0.2 mg, 0.3 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 12 Hour, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kapvay: 0.1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.1 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153441\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051811\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Epidural: Not for IV use. Visually inspect for particulate matter and discoloration prior to administration (whenever permitted by container and solution). Specialized  techniques are required for continuous epidural administration; administration via this route should only be performed by qualified individuals familiar with the techniques of epidural administration and patient management problems associated with this route. Familiarization of the epidural infusion device is essential. Do not discontinue clonidine abruptly; if needed, gradually reduce dose over 2 to 4 days to avoid withdrawal symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: May be administered without regard to meals. Swallow extended release formulations whole; do not crush or chew. Kapvay should not be split. Do not discontinue clonidine abruptly; if needed, gradually reduce immediate release dose over 2 to 4 days to avoid rebound hypertension; extended release formulation (Kapvay) should be tapered in decrements of &le;0.1 mg every 3 to 7 days.  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Transdermal: Patches should be applied at bedtime to a clean, hairless area of the upper arm or chest; rotate patch sites weekly in adults; in children, the patch may need to be changed more frequently (eg, every 3 to 5 days); in adults, redness under patch may be reduced if a topical corticosteroid spray is applied to the area before placement of the patch (Tom 1994); <b>Note:</b> Transdermal patch is a membrane-controlled system; do <b>not</b> cut the patch to deliver partial doses; rate of drug delivery, reservoir contents, and adhesion may be affected if cut; if partial dose is needed, surface area of patch can be blocked proportionally using adhesive bandage (Lee 1997).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10205861\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Epidural formulation: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). <b>Preservative free;</b> discard unused portion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release tablets: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal patches: Store below 30&deg;C (86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051810\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Management of hypertension (monotherapy or as adjunctive therapy) (FDA approved in adults); has also been used for the treatment of attention-deficit/hyperactivity disorder, Tourette syndrome and tic disorders, conduct disorder/oppositional defiant disorder, neonatal abstinence syndrome (opioid withdrawal), and as an aid in the diagnosis of pheochromocytoma and growth hormone deficiency</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Kapvay: Treatment of attention deficit hyperactivity disorder (ADHD) (monotherapy or as adjunctive therapy) (FDA approved in ages 6 to 17 years)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Epidural (Duraclon): For continuous epidural administration as adjunctive therapy with opioids for treatment of severe cancer pain in patients tolerant to or unresponsive to opioids alone; epidural clonidine is generally more effective for neuropathic pain and less effective (or possibly ineffective) for somatic or visceral pain [FDA approved in pediatric patients (age not specified) and adults]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topical: Transdermal patch: Management of hypertension (monotherapy or as adjunctive therapy) (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153543\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">CloNIDine may be confused with Clomid, clomiPHENE, clonazePAM, cloZAPine, KlonoPIN, quiNIDine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Catapres may be confused with Cataflam, Combipres</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (epidural administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Clonidine is identified in the  Beers Criteria as a potentially inappropriate medication in patients 65 years and older (independent of diagnosis or condition) due to high risk of CNS adverse effects and risk of bradycardia and orthostatic hypotension associated with central alpha blockers. Avoid clonidine as a first-line antihypertensive (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Use caution when interpreting dosing information. Pediatric dose for epidural infusion expressed as mcg/kg/<b>hour</b>.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI. Errors have occurred when the inactive, optional adhesive cover has been applied instead of the active clonidine-containing patch.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153540\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Oral, Transdermal:</b> Incidence of adverse events may be less with transdermal compared to oral due to the lower peak/trough ratio.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Atrioventricular block, bradycardia, cardiac arrhythmia, cardiac failure, cerebrovascular accident, chest pain, ECG abnormality, edema, flushing, localized blanching (transdermal), orthostatic hypotension, palpitations, prolonged Q-T Interval on ECG, Raynaud's phenomenon, syncope, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Aggressive behavior, agitation, anxiety, behavioral changes, delirium, delusions, depression, dizziness, drowsiness, emotional disturbance, fatigue, hallucination (visual and auditory), headache, insomnia, irritability, lethargy, malaise, nervousness, nightmares, numbness (localized; transdermal), paresthesia, parotid pain (oral), restlessness, sedation, throbbing (transdermal), vivid dream, withdrawal syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Allergic contact sensitivity (transdermal), alopecia, burning sensation of skin (transdermal), contact dermatitis (transdermal), excoriation (transdermal), hyperpigmentation (transdermal), hypopigmentation (localized; transdermal), localized vesiculation (transdermal), macular eruption, pallor, papule (transdermal), skin rash, transient skin rash (localized; characterized by pruritus and erythema; transdermal), urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Decreased libido, gynecomastia, hyperglycemia (transient; oral), increased thirst, weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (oral), anorexia, constipation, diarrhea, gastrointestinal pseudo-obstruction (oral), nausea, parotitis (oral), sore throat, upper abdominal pain, viral gastrointestinal infection, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Erectile dysfunction, nocturia, pollakiuria, sexual disorder, urinary incontinence, urinary retention</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Thrombocytopenia (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Abnormal hepatic function tests (mild transient abnormalities), hepatitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Angioedema</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia, increased creatine phosphokinase (transient; oral), leg cramps, limb pain, myalgia, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Accommodation disturbance, blurred vision, burning sensation of eyes, decreased lacrimation, dry eye syndrome, increased lacrimation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otalgia, otitis media</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Asthma, dry nose, epistaxis, flu-like symptoms, nasal congestion, nasopharyngitis, respiratory tract infection, rhinorrhea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Crying, fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Epidural: Note:</b> The following adverse events occurred more often than placebo in cancer patients with intractable pain being treated with concurrent epidural morphine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain, hypotension, orthostatic hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Confusion, dizziness, hallucination</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea and vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Tinnitus</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153463\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to clonidine hydrochloride or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Epidural administration: Injection site infection; concurrent anticoagulant therapy; bleeding diathesis; administration above the C4 dermatome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153445\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bradycardia: May cause dose-dependent reductions in heart rate; use with caution in patients with preexisting bradycardia or those predisposed to developing bradycardia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: Symptomatic hypotension may occur with use. In all patients, use epidural clonidine with caution due to the potential for severe hypotension, especially in women and those of low body weight. Most hypotensive episodes occur within the first 4 days of initiation; however, episodes may occur throughout the duration of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory depression: Epidural administration may result in mild respiratory depression (usually associated with higher than recommended doses).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Xerostomia: May cause significant xerostomia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with severe coronary insufficiency, including recent MI and conduction disturbances, including sinus node dysfunction. The use of epidural clonidine frequently reduces heart rate; AV block greater than first-degree has been reported rarely. Epidural clonidine is not recommended for use in patients with severe cardiovascular disease or hemodynamic instability. May lead to cardiovascular instability (hypotension, bradycardia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebrovascular disease: Use with caution in patients with cerebrovascular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with chronic renal impairment. The hemodynamic effects may be prolonged in those with renal impairment; elimination half-life significantly prolonged (up to 41 hours) in patients with severe renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Agents with SA/AV nodal blocking properties: Use with caution in patients concurrently receiving agents known to reduce SA node function and/or AV nodal conduction (eg, digoxin, diltiazem, metoprolol, verapamil); may increase risk of serious bradycardia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depressants: Sedating effects may be potentiated when used with other CNS-depressant drugs or ethanol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Since children commonly have gastrointestinal illnesses with vomiting, they are susceptible to hypertensive episodes due to abrupt inability to take oral medication. Epidural clonidine should be reserved for pediatric cancer patients with severe intractable pain, unresponsive to other analgesics or epidural or spinal opioids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical patients: Discontinue oral immediate-release formulations within 4 hours of surgery, then restart as soon as possible afterward.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Epidural use: <b>[US Boxed Warning]: Must dilute concentrated epidural injectable (500 mcg/mL) solution prior to use. Epidural clonidine is not recommended for perioperative, obstetrical, or postpartum pain due to risk of hemodynamic instability.</b> Should be administered via continuous epidural infusion device. Monitor closely for catheter-related infection such as meningitis or epidural abscess.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product interchangeability: Oral formulations of clonidine (immediate release versus extended release) are not interchangeable on a mg:mg basis due to different pharmacokinetic profiles.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transdermal patch: May contain conducting metal (eg, aluminum); remove patch prior to MRI. Due to the potential for altered electrical conductivity, remove transdermal patch before cardioversion or defibrillation. Localized contact sensitization to the transdermal system has been reported; in these patients, allergic reactions (eg, generalized rash, urticaria, angioedema) have also occurred following subsequent substitution of oral therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contact lens wearers: Clonidine may cause eye dryness in patients who wear contact lenses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: Gradual withdrawal is needed (taper oral immediate release or epidural dose gradually over 2 to 4 days to avoid rebound hypertension) if drug needs to be stopped. Patients should be instructed about abrupt discontinuation (causes rapid increase in BP and symptoms of sympathetic overactivity). In patients on both a beta-blocker and clonidine where withdrawal of clonidine is necessary, withdraw the beta-blocker first and several days before clonidine withdrawal, then slowly decrease clonidine. In children and adolescents, extended release formulation (Kapvay) should be tapered in decrements of no more than 0.1 mg every 3 to 7 days. The clonidine withdrawal syndrome is more pronounced after abrupt cessation of long-term therapy than after short-term therapy (1 to 2 months). It has usually been associated with previous administration of high oral doses (&gt;1.2 mg daily in adults) and/or continuation of beta-blocker therapy. The danger of abrupt discontinuation may be increased in patients with hypertension and/or other cardiovascular considerations. Blood pressure may increase 8 to 24 hours after last dose, but has occurred 60 hours after the last clonidine dose. Rebound hypertension has occurred with discontinuation of transdermal and epidural clonidine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25855478\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The American Heart Association recommends that all children diagnosed with ADHD who may be candidates for medication, such as clonidine, should have a thorough cardiovascular assessment prior to initiation of therapy. These recommendations are based upon reports of serious cardiovascular adverse events (including sudden death) in patients (both children and adults) taking usual doses of stimulant medications. Most of these patients were found to have underlying structural heart disease (eg, hypertrophic obstructive cardiomyopathy). This assessment should include a combination of thorough medical history, family history, and physical examination. An ECG is not mandatory but should be considered. <b>Note:</b> ECG abnormalities and four cases of sudden cardiac death have been reported in children receiving clonidine with methylphenidate; reduce dose of methylphenidate by 40% when used concurrently with clonidine; consider ECG monitoring. In patients with ADHD, clonidine may cause hypotension and bradycardia; use with caution in patients with history of hypotension, heart block, bradycardia, cardiovascular disease, syncope, conditions predisposing to syncope (including orthostatic hypotension, dehydration), or receiving concomitant antihypertensive therapy. Patients should be advised to avoid becoming dehydrated or overheated. Heart rate and blood pressure should be monitored at initiation of therapy, with any dose increase, and periodically during therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299067\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153450\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13171&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Alpha2-Agonists may enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn.  Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.<b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): CloNIDine may enhance the AV-blocking effect of Calcium Channel Blockers (Nondihydropyridine). Sinus node dysfunction may also be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: CloNIDine may enhance the AV-blocking effect of Cardiac Glycosides. Sinus node dysfunction may also be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EPHEDrine (Systemic): CloNIDine may enhance the therapeutic effect of EPHEDrine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Alpha2-Agonists may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: CloNIDine may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of CloNIDine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: May diminish the antihypertensive effect of Alpha2-Agonists. Management: Consider avoiding concurrent use.  If the combination cannot be avoided, monitor for decreased effects of alpha2-agonists if mirtazapine is initiated/dose increased, or increased effects if mirtazapine is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin/Norepinephrine Reuptake Inhibitors: May diminish the antihypertensive effect of Alpha2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terlipressin: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May diminish the antihypertensive effect of Alpha2-Agonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153451\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153467\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Clonidine crosses the placenta; concentrations in the umbilical cord plasma are similar to those in the maternal serum and concentrations in the amniotic fluid may be 4 times those in the maternal serum. The pharmacokinetics of clonidine may be altered during pregnancy (Buchanan 2009). Untreated chronic maternal hypertension is associated with adverse events in the fetus, infant, and mother. If treatment for hypertension during pregnancy is needed, other agents are preferred (ACOG 2012). <b>[US Boxed Warning]: Epidural clonidine is not recommended for obstetrical or postpartum pain</b> due to risk of hemodynamic instability.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051806\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, heart rate; consider ECG monitoring in patients with history of heart disease or concurrent use of medications affecting cardiac conduction. With epidural administration: Blood pressure, heart rate; pulse oximetry with large bolus doses; monitor infusion pump and catheter tubing for obstruction or dislodgment throughout the course of therapy to decrease risk of inadvertent abrupt discontinuation; monitor closely for catheter-related infection, such as meningitis or epidural abscess.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ADHD: Evaluate patients for cardiac disease prior to initiation of therapy for ADHD with thorough medical history, family history, and physical exam; consider ECG; perform ECG and echocardiogram if findings suggest cardiac disease; promptly conduct cardiac evaluation in patients who develop chest pain, unexplained syncope, or any other symptom of cardiac disease during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clonidine tolerance test: In addition to growth hormone concentrations, monitor blood pressure and blood glucose (Huang 2001)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153444\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Stimulates alpha<sub>2</sub>-adrenoceptors in the brain stem, thus activating an inhibitory neuron, resulting in reduced sympathetic outflow from the CNS, producing a decrease in peripheral resistance, renal vascular resistance, heart rate, and blood pressure; epidural clonidine may produce pain relief at spinal presynaptic and postjunctional alpha<sub>2</sub>-adrenoceptors by preventing pain signal transmission; pain relief occurs only for the body regions innervated by the spinal segments where analgesic concentrations of clonidine exist. For the treatment of ADHD, the mechanism of action is unknown; it has been proposed that postsynaptic alpha<sub>2</sub>-agonist stimulation regulates subcortical activity in the prefrontal cortex, the area of the brain responsible for emotions, attentions, and behaviors and causes reduced hyperactivity, impulsiveness, and distractibility. Epidurally administered clonidine produces dose-dependent analgesia not antagonized by opiate antagonists. The analgesia is limited to the body regions innervated by the spinal segments where analgesic concentrations of clonidine are present. Clonidine is thought to produce analgesia at presynaptic and postjunctional alpha-2-adrenoceptors in the spinal cord by preventing pain signal transmission to the brain.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153462\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Antihypertensive effect: Transdermal: Steady state reached in ~3 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Attention-deficit/hyperactivity disorder: Oral: Extended release (Kapvay): Onset of action: 1 to 2 weeks (AAP 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Extended-release tablets (Kapvay) are not bioequivalent with immediate-release formulations; peak plasma concentrations are 50% lower compared to immediate-release formulations</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: ~2.9 L/kg; highly lipid soluble; distributes readily into extravascular sites</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Epidurally administered clonidine readily distributes into plasma via the epidural veins and attains clinically significant systemic concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 20% to 40%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensively hepatic to inactive metabolites; undergoes enterohepatic recirculation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: Immediate release: 70% to 80%; Extended release (Kapvay): ~89% (relative to immediate-release formulation); Transdermal: ~60%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: 6.13 &plusmn; 1.33 hours (Lonnqvist 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Normal renal function: 12 to 16 hours; Renal impairment: &le;41 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Epidural administration: CSF half-life elimination: 1.3 &plusmn; 0.5 hours; plasma half-life elimination: 22 &plusmn; 15 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Transdermal: Half-life elimination (after patch removal): ~20 hours (due to skin depot effect; increase in plasma clonidine concentrations may occur after patch removal [MacGregor 1985])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Oral: Immediate release: 1 to 3 hours; Extended release (Kapvay): 7 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (40% to 60% as unchanged drug)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance:</p>\n    <p style=\"text-indent:-4em;margin-left:8em;\">Oral:</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">Neonates: 0.16 L/kg/hour (Xie 2011)</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">Infants and Children &le;4 years: ~0.3 L/kg/hour (Xie 2011)</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">Children 5 to 10 years: ~0.26 L/kg/hour (Xie 2011)</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">Adults: Single dose: ~0.25 L/kg/hour; Multiple dose: ~0.4 L/kg/hour (Frisk-Holmberg 1981)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051817\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Clonidine-induced symptomatic bradycardia may be treated with atropine. Clonidine hydrochloride 0.1 mg is equal to 0.087 mg of the free base. Medications used to treat ADHD should be part of a total treatment program that may include other components, such as psychological, educational, and social measures. Long-term usefulness of clonidine for the treatment of ADHD should be periodically re-evaluated in patients receiving the drug for extended periods of time.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11339546\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Compounded oral suspension may be available in multiple concentrations (eg, up to 10 times more concentrated); use caution to avoid confusion; verify concentration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>0.02 mg/mL (20 mcg/mL) Oral Liquid (ASHP Standard Concentration)</b> (ASHP 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A <b>0.02</b> mg/mL (20 mcg/mL) oral liquid may be made from tablets. Crush six 0.1 mg tablets in a glass mortar and levigate with 1 to 2 mL Simple Syrup, NF. Add additional Simple Syrup, NF and transfer to a calibrated amber bottle. Rinse the mortar and pestle with the vehicle and add quantity of vehicle sufficient to make 30 mL. Label &ldquo;refrigerate.&rdquo; Stable for 35 days when stored in an ambler plastic bottle and refrigerated.</p>\n    <div class=\"reference\">Sauberan JB, Phuong P, Ilog ND, Rossi SS. Stability and osmolality of extemporaneously prepared clonidine oral liquid for neonates. <i>Ann Pharmacother</i>. 2016;50(3):243-244. doi: 10.1177/1060028015620625.<span class=\"pubmed-id\">26728366</span></div>\r\n\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>0.01 mg/mL (10 mcg/mL) Oral Suspension</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A <b>0.01</b> mg/mL (10 mcg/mL) oral suspension may be made from tablets. Crush twenty 0.1 mg tablets in a glass mortar and reduce to a fine powder. Slowly add Ora-Blend in ~15 mL increments while mixing to form a uniform paste until approximately half of the total volume (~100 mL) is added. Transfer the suspension to a graduated cylinder. Rinse the mortar and pestle with the remaining vehicle and add quantity to fill the volume within the graduated cylinder to 200 mL. Transfer this amount to a calibrated bottle. Label &ldquo;shake well.&rdquo; When stored in clear plastic syringes, the suspension is stable for at least 91 days at room temperature (25&deg;C) or refrigerated (4&deg;C).</p>\n    <div class=\"reference\">Ma C, Decarie D, Ensom MHH. Stability of clonidine oral suspension in oral plastic syringes. <i>Am J Health-Syst Pharm</i>. 2014;71:657-661.<span class=\"pubmed-id\">24688040</span></div>\r\n\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>0.1 mg/mL (100 mcg/mL) Oral Suspension</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A <b>0.1</b> mg/mL (100 mcg/mL) oral suspension may be made from tablets. Crush thirty 0.2 mg tablets in a glass mortar and reduce to a fine powder. Slowly add 2 mL Purified Water USP and mix to a uniform paste. Slowly add Simple Syrup, NF in 15 mL increments; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 60 mL. Label &quot;shake well&quot; and &quot;refrigerate&quot;. Stable for 28 days when stored in amber glass bottles and refrigerated.</p>\n    <div class=\"reference\">Levinson ML and Johnson CE. Stability of an extemporaneously compounded clonidine hydrochloride oral liquid. <i>Am J Hosp Pharm</i>. 1992;49(1):122-125.<span class=\"pubmed-id\">1570852</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153466\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch weekly</b> (Catapres-TTS-1 Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg/24 hrs (4): $292.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch weekly</b> (Catapres-TTS-2 Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2 mg/24 hrs (4): $492.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch weekly</b> (Catapres-TTS-3 Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3 mg/24 hrs (4): $683.29</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch weekly</b> (CloNIDine HCl Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg/24 hrs (1): $33.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2 mg/24 hrs (1): $55.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3 mg/24 hrs (1): $77.36</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (CloNIDine HCl (Analgesia) Epidural)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/mL (10 mL): $30.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mcg/mL (10 mL): $120.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Duraclon Epidural)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/mL (10 mL): $52.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mcg/mL (10 mL): $264.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 12-hour</b> (CloNIDine HCl ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg (60): $269.98</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 12-hour</b> (Kapvay Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg (60): $530.35</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Catapres Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg (100): $301.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2 mg (100): $461.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3 mg (100): $579.30</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (CloNIDine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg (100): $24.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2 mg (100): $37.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3 mg (100): $52.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038585\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alphapres (PH);</li>\n      <li>Arkamin (IN);</li>\n      <li>Aruclonin (HU);</li>\n      <li>Atensina (BR);</li>\n      <li>Catamed (PH);</li>\n      <li>Catapin (PH);</li>\n      <li>Catapres (AU, BB, BD, BF, BH, BJ, BM, BS, BZ, CI, CY, ET, GB, GH, GM, GN, GY, HK, ID, IE, IL, IN, IQ, IR, JM, JO, JP, KE, KR, KW, LR, MA, ML, MR, MT, MU, MW, MY, NE, NG, NZ, OM, PH, PK, PR, QA, SA, SC, SD, SG, SL, SN, SR, TN, TT, TW, TZ, UG, ZM, ZW);</li>\n      <li>Catapresan (AR, AT, CH, CL, CO, CR, DE, DK, DO, EC, ES, FI, GR, GT, HN, HR, IS, IT, NI, NL, NO, PA, PE, PT, SE, SI, SV, VE);</li>\n      <li>Catapresan Depot (CZ, DE);</li>\n      <li>Catapresan TTS (IT);</li>\n      <li>Catapress (AE, EG);</li>\n      <li>Catapressan (BE, FR, LU, VN);</li>\n      <li>Chlophazolin (BG, LV);</li>\n      <li>Clonidina Larjan (AR);</li>\n      <li>Clonidural (AR);</li>\n      <li>Clonigen (PH);</li>\n      <li>Clonipresan (PY);</li>\n      <li>Clonipress (PH);</li>\n      <li>Dixarit (IE, LU, NZ);</li>\n      <li>Haemiton (DE, IL);</li>\n      <li>Hylon (BD);</li>\n      <li>Hypodine (TH);</li>\n      <li>Iporel (PL);</li>\n      <li>Isoglaucon (HU);</li>\n      <li>Jenloga (BM);</li>\n      <li>Kapvay (BM);</li>\n      <li>Kapvay ER (KR);</li>\n      <li>Melzin (PH);</li>\n      <li>Menograine (ZA);</li>\n      <li>Normopresan (IL);</li>\n      <li>Normopresin (UY);</li>\n      <li>Paracefan (BE);</li>\n      <li>Run Rui (CN);</li>\n      <li>Terclodine (PH);</li>\n      <li>Winpress (TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Agthe AG, Kim GR, Mathias KB, et al, &quot;Clonidine as an Adjunct Therapy to Opioids for Neonatal Abstinence Syndrome: A Randomized, Controlled Trial,&quot; <i>Pediatrics</i>, 2009, 123(5):e849-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/19398463/pubmed\" target=\"_blank\" id=\"19398463\">19398463</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics, &quot;ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents,&quot; <i>Pediatrics</i>, 2011; 128(5): 1-16.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD. Available at http://www.aap.org/pressroom/aap-ahastatement.htm</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), &quot;ACOG Practice Bulletin No. 125: Chronic Hypertension in Pregnancy,&quot; <i>Obstet Gynecol</i>, 2012, 119(2 Pt 1):396-407.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/22270315/pubmed\" target=\"_blank\" id=\"22270315\">22270315</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arenas-L&oacute;pez S, Riphagen S, Tibby SM, et al. Use of oral clonidine for sedation in ventilated paediatric intensive care patients. <i>Intensive Care Med</i>. 2004;30(8):1625-1629.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/15197439/pubmed\" target=\"_blank\" id=\"15197439\">15197439</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Atkinson HC, Begg EJ, and Darlow BA, &quot;Drugs in Human Milk. Clinical Pharmacokinetic Considerations,&quot; <i>Clin Pharmacokinet</i>, 1988, 14(4):217-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/3292101 /pubmed\" target=\"_blank\" id=\"3292101 \">3292101 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bada HS, Sithisarn T, Gibson J, et al. Morphine versus clonidine for neonatal abstinence syndrome. <i>Pediatrics</i>. 2015;135(2):e383-391.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/25624389/pubmed\" target=\"_blank\" id=\"25624389\">25624389</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buchanan ML, Easterling TR, Carr DB, et al, &quot;Clonidine Pharmacokinetics in Pregnancy,&quot; <i>Drug Metab Dispos</i>, 2009, 37(4):702-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/19116263/pubmed\" target=\"_blank\" id=\"19116263\">19116263</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bunjes R, Schaefer C, and Holzinger D, &quot;Clonidine and Breast-Feeding,&quot; <i>Clin Pharm</i>, 1993, 12(3):178-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/8491075/pubmed\" target=\"_blank\" id=\"8491075\">8491075</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Capino AC, Miller JL, Johnson PN. Clonidine for sedation and analgesia and withdrawal in critically ill infants and children. <i>Pharmacotherapy</i>. 2016 Oct 25. [Epub ahead of print]<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/8491075/pubmed\" target=\"_blank\" id=\"8491075\">8491075</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chafin CC, Hovinga CA, and Phelps SJ, &quot;Clonidine in the Treatment of Attention Deficit Hyperactivity Disorder,&quot; <i>Journal of Pediatric Pharmacy Practice</i>, 1999, 4(6):308-15.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chobanian AV, Bakris GL, Black HR, et al, &quot;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&quot; <i>JAMA</i>, 2003, 289(19):2560-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/12748199/pubmed\" target=\"_blank\" id=\"12748199\">12748199</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Connor DF, Barkley RA, Davis HT. A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. <i>Clin Pediatr (Phila)</i>. 2000;39(1):15-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/10660814/pubmed\" target=\"_blank\" id=\"10660814\">10660814</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corazza M, Mantovani L, Virgili A, Strumia R. Allergic contact dermatitis from a clonidine transdermal delivery system. <i>Contact Dermatitis</i>. 1995;32(4):246.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/7600788 /pubmed\" target=\"_blank\" id=\"7600788 \">7600788 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cunningham FE, Baughman VL, Peters J, et al, &quot;Comparative Pharmacokinetics of Oral Versus Sublingual Clonidine,&quot; <i>J Clin Anesth</i>, 1994, 6(5):430-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/7986518/pubmed\" target=\"_blank\" id=\"7986518\">7986518</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Duffett M, Choong K, Foster J, et al. Clonidine in the sedation of mechanically ventilated children: a pilot randomized trial. <i>J Crit Care</i>. 2014;29(5):758-763.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/25015006/pubmed\" target=\"_blank\" id=\"25015006\">25015006</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Duraclon (clonidine hydrochloride injection) [prescribing information]. Lake Forest, IL: Bioniche Pharma; August 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gaffney GR, Perry PJ, Lund BC, Bever-Stille KA, Arndt S, Kuperman S. Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. <i>J Am Acad Child Adolesc Psychiatry.</i> 2002;41(3):330-336.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/11886028 /pubmed\" target=\"_blank\" id=\"11886028 \">11886028 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Galloway KS and Yaster M, &quot;Pain and Symptom Control in Terminally Ill Children,&quot; <i>Pediatr Clin North Am</i>, 2000, 47(3):711-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/10835999/pubmed\" target=\"_blank\" id=\"10835999\">10835999</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hart-Santora D and Hart LL, &quot;Clonidine in Attention Deficit Hyperactivity Disorder,&quot; <i>Ann Pharmacother</i>, 1992, 26(1):37-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/1606344/pubmed\" target=\"_blank\" id=\"1606344\">1606344</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. <i>J Am Acad Child Adolesc Psychiatry</i>. 2003;42(8):886-894.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/12874489 /pubmed\" target=\"_blank\" id=\"12874489 \">12874489 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hedderick EF, Morris CM, Singer HS. Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. <i>Pediatr Neurol</i>. 2009;40(6):420-425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/19433274 /pubmed\" target=\"_blank\" id=\"19433274 \">19433274 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoder EL, Leckman JF, Ehrenkranz R, Kleber H, Cohen DJ, Poulsen JA. Clonidine in neonatal narcotic-abstinence syndrome. <i>N Engl J Med</i>. 1981;305(21):1284.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/19433274 /pubmed\" target=\"_blank\" id=\"19433274 \">19433274 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoder EL, Leckman JF, Poulsen J, et al. Clonidine treatment of neonatal narcotic abstinence syndrome. <i>Psychiatry Res</i>. 1984;13(3):243-251.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/6597462/pubmed\" target=\"_blank\" id=\"6597462\">6597462</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Huang C, Banerjee K, Sochett E, et al, &quot;Hypoglycemia Associated With Clonidine Testing for Growth Hormone Deficiency,&quot; <i>J Pediatr</i>, 2001, 139(2):323-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/11487765/pubmed\" target=\"_blank\" id=\"11487765\">11487765</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hudak ML and Tan RC, &quot;Neonatal Drug Withdrawal,&quot; <i>Pediatrics</i>, 2012, 129(2):e540-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/22291123/pubmed\" target=\"_blank\" id=\"22291123\">22291123</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hunt RD, Capper L, and O'Connell P, &quot;Clonidine in Child and Adolescent Psychiatry,&quot; <i>J Child Adol Psychpharm</i>, 1990, 1(1):87-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hunt RD, Minderaa RB, and Cohen DJ, &quot;The Therapeutic Effect of Clonidine in Attention Deficit Disorder With Hyperactivity: A Comparison With Placebo and Methylphenidate,&quot; <i>Psychopharmacol Bull</i>, 1986, 22(1):229-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/3523578/pubmed\" target=\"_blank\" id=\"3523578\">3523578</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kapvay (clonidine) [prescribing information]. St. Michael, Barbados: Concordia; June 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kavey RE, Daniels SR, and Flynn JT, &quot;Management of High Blood Pressure in Children and Adolescents,&quot; <i>Cardiol Clin</i>, 2010, 28(4):597-607.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/20937444/pubmed\" target=\"_blank\" id=\"20937444\">20937444</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K/DOQI Workgroup, &quot;K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients,&quot; <i>Am J Kidney Dis</i>, 2005, 45(4 Suppl 3):S46-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/15806502/pubmed\" target=\"_blank\" id=\"15806502\">15806502</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kemph JP, DeVane CL, Levin GM, Jarecke R, Miller RL. Treatment of aggressive children with clonidine: results of an open pilot study. <i>J Am Acad Child Adolesc Psychiatry</i>. 1993;32(3):577-581.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/8496122/pubmed\" target=\"_blank\" id=\"8496122\">8496122</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lanes R and Hurtado E, &quot;Oral Clonidine &minus; An Effective Growth Hormone-Releasing Agent in Prepubertal Subjects,&quot; <i>J Pediatr</i>, 1982, 100(5):710-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/7040621/pubmed\" target=\"_blank\" id=\"7040621\">7040621</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee HA and Anderson PO, &quot;Giving Partial Doses of Transdermal Patches,&quot; <i>Am J Health Syst Pharm</i>, 1997, 54(15):1759-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/9262751/pubmed\" target=\"_blank\" id=\"9262751\">9262751</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leikin JB, Mackendrick WP, Maloney GE, et al, &quot;Use of Clonidine in the Prevention and Management of Neonatal Abstinence Syndrome,&quot; <i>Clin Toxicol (Phila)</i>, 2009, 47(6):551-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/19566381/pubmed\" target=\"_blank\" id=\"19566381\">19566381</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacGregor TR, Matzek KM, Keirns JJ, et al, &ldquo;Pharmacokinetics of Transdermally Delivered Clonidine,&rdquo; <i>Clin Pharmacol Ther</i>, 1985, 38(3):278-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/4028622/pubmed\" target=\"_blank\" id=\"4028622\">4028622</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morselli PL, Boutroy MJ, Bianchetti G, Th&eacute;not JP. Pharmacokinetics of antihypertensive drugs in the neonatal period. <i>Dev Pharmacol Ther</i>. 1989;13(2-4):190-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/2693002/pubmed\" target=\"_blank\" id=\"2693002\">2693002</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murphy TK, Lewin AB, Storch EA, Stock S; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with tic disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2013;52(12):1341-1359<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/24290467/pubmed\" target=\"_blank\" id=\"24290467\">24290467</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Heart, Lung, and Blood Institute, &ldquo;Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents,&rdquo; <i>Clinical Practice Guidelines</i>, 2011, National Institutes of Health. Available at <a href=\"http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a>. Date accessed: June 11, 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National High Blood Pressure Education Program (NHBPEP) Working Group on High Blood Pressure in Children and Adolescents, &quot;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&quot; <i>Pediatrics</i>, 2004, 114(2 Suppl 4th Report):555-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/15286277/pubmed\" target=\"_blank\" id=\"15286277\">15286277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health. Attention deficit hyperactivity disorder, The NICE Guideline on Diagnosis and Management of ADHD in Children, Young People and Adults. National Clinical Practice Guideline Number 72. 2008:1-664. Available at www.nice.org.uk/cg072</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Palumbo DR, Sallee FR, Pelham WE Jr, Bukstein OG, Daviss WB, McDermott MP. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. <i>J Am Acad Child Adolesc Psychiatry</i>. 2008;47(2):180-188.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/18182963/pubmed\" target=\"_blank\" id=\"18182963\">18182963</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perrin JM, Friedman RA, Knilans TK, Black Box Working Group, Section on Cardiology and Cardiac Surgery. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. <i>Pediatrics</i>. 2008;122(2):451-453.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/18676566 /pubmed\" target=\"_blank\" id=\"18676566 \">18676566 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Playfor S, Jenkins I, Boyles C, et al. Consensus guidelines on sedation and analgesia in critically ill children. <i>Intensive Care Med</i>. 2006;32(8):1125-1136.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/16699772/pubmed\" target=\"_blank\" id=\"16699772\">16699772</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pliszka S; AACAP Work Group on Quality Issues, &quot;Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 2007, 46(7):894-921.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/17581453/pubmed\" target=\"_blank\" id=\"17581453\">17581453</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pringsheim T, Doja A, Gorman D, et al. Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. <i>Can J Psychiatry</i>. 2012;57(3):133-143.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/22397999/pubmed\" target=\"_blank\" id=\"22397999\">22397999</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richmond EJ and Rogol AD, &quot;Growth Hormone Deficiency in Children,&quot; <i>Pituitary</i>, 2008, 11(2):115-20.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rocchini AP, &quot;Childhood Hypertension: Etiology, Diagnosis, and Treatment,&quot; <i>Pediatr Clin North Am</i>, 1984, 31(6):1259-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/6390314/pubmed\" target=\"_blank\" id=\"6390314\">6390314</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roessner V, Plessen KJ, Rothenberger A, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. <i>Eur Child Adolesc Psychiatry</i>. 2011;20(4):173-196.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/21445724 /pubmed\" target=\"_blank\" id=\"21445724 \">21445724 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosendorff C, Lackland DT, Allison M, et al. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>J Am Soc Hypertens</i>. 2015;9(6):453-498.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/25840695 /pubmed\" target=\"_blank\" id=\"25840695 \">25840695 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scahill L, &quot;Alpha-2 Adrenergic Agonists in Attention Deficit Hyperactivity Disorder,&quot; <i>J Pediatr</i>, 2009, 154:S32-7.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sinaiko AR, &quot;Pharmacologic Management of Childhood Hypertension,&quot; <i>Pediatr Clin North Am</i>, 1993, 40(1):195-212.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/8417406/pubmed\" target=\"_blank\" id=\"8417406\">8417406</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Surran B, Visintainer P, Chamberlain S, Kopcza K, Shah B, Singh R. Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. <i>J Perinatol</i>. 2013;33(12):954-959.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/23949834/pubmed\" target=\"_blank\" id=\"23949834\">23949834</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Swain JE, Scahill L, Lombroso PJ, et al, &quot;Tourette Syndrome and Tic Disorders: A Decade of Progress,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 2007, 46(8):947-68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/17667475/pubmed\" target=\"_blank\" id=\"17667475\">17667475</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tom GR and Premer M, &quot;Hydrocortisone Cream in Clonidine Patch Dermatitis,&quot; <i>Ann Pharmacother</i>, 1994, 28(7-8):889-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/7949510/pubmed\" target=\"_blank\" id=\"7949510\">7949510</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tourette's Syndrome Study Group, &quot;Treatment of ADHD in Children With Tics: A Randomized Controlled Trial,&quot; <i>Neurology</i>, 2002, 58(4):527-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/11865128/pubmed\" target=\"_blank\" id=\"11865128\">11865128</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vetter VL, Elia J, Erickson C, et al, &quot;Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing,&quot; <i>Circulation</i>, 2008, 117(18):2407-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/18427125/pubmed\" target=\"_blank\" id=\"18427125\">18427125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weber MA, Schiffrin EL, White WB, et al. Clinical Practice Guidelines for the Management of Hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hyperten (Greenwich)</i>. 2014;16(1):14-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/24341872/pubmed\" target=\"_blank\" id=\"24341872\">24341872</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weisman H, Qureshi IA, Leckman JF, Scahill L, Bloch MH. Systematic review: pharmacological treatment of tic disorders--efficacy of antipsychotic and alpha-2 adrenergic agonist agents. <i>Neurosci Biobehav Rev</i>. 2013;37(6):1162-1171.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-pediatric-drug-information/abstract-text/23099282 /pubmed\" target=\"_blank\" id=\"23099282 \">23099282 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13171 Version 251.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708678\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F153485\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F153486\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1051807\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F12669157\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1051799\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F153455\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F153441\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1051811\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F10205861\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1051810\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F153543\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F153540\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F153463\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F153445\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25855478\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299067\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F153450\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F153451\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F153467\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1051806\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F153444\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F153462\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1051817\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F11339546\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F153466\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038585\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13171|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=clonidine-drug-information\" class=\"drug drug_general\">Clonidine: Drug information</a></li><li><a href=\"topic.htm?path=clonidine-patient-drug-information\" class=\"drug drug_patient\">Clonidine: Patient drug information</a></li></ul></div></div>","javascript":null}